Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

195.92
-8.9400-4.36%
Post-market: 195.00-0.9200-0.47%16:25 EDT
Volume:2.97M
Turnover:588.03M
Market Cap:41.99B
PE:-21.96
High:205.15
Open:204.84
Low:193.58
Close:204.86
52wk High:224.31
52wk Low:42.18
Shares:214.34M
Float Shares:185.00M
Volume Ratio:2.49
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.11
PE(LYR):-32.93

Loading ...

Movement Alert|Revolution Medicines, Inc. Falls 5.1% in Regular Trading, Trading at $194.58

Market Focus
·
1 hour ago

Revolution Medicines gets orphan designation for pancreatic cancer treatment

TIPRANKS
·
Yesterday

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Sep 15

Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer

MT Newswires Live
·
Sep 15

Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA

TIPRANKS
·
Sep 15

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for Rasonque™ (Daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Sep 15

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)

TIPRANKS
·
Sep 14

Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million

Reuters
·
Sep 11

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Dow Jones
·
Sep 11

Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says

MT Newswires Live
·
Sep 10

Morgan Stanley Initiates Coverage on Revolution Medicines With Overweight Rating

MT Newswires Live
·
Sep 10

Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255

THOMSON REUTERS
·
Sep 10

BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion

Reuters
·
Sep 10

Revolution Medicines Price Target Raised to $230.00/Share from $215.00 by Stifel

Dow Jones
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Sep 09

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

TIPRANKS
·
Sep 03

Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target

TIPRANKS
·
Sep 03

NEJM publishes Phase 1/2 clinical data on daraxonrasib

TIPRANKS
·
Sep 03

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire
·
Sep 03

Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million

Reuters
·
Sep 03